Prosecution Insights
Last updated: April 19, 2026

Denali Therapeutics Inc.

7 pending office actions

Portfolio Summary

7
Total Pending OAs
1
Final Rejections
6
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18646220 CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE COLEMAN, BRENDA LIBBY 1624 Non-Final OA Apr 25, 2024
18701573 MICROGLIAL CELL MORPHOMETRY LIU, XIAO 2664 Non-Final OA Apr 15, 2024
18248818 METHODS FOR TREATING AND MONITORING FRONTOTEMPORAL DEMENTIA COLENA, TRACY CHING-TIAN 1797 Non-Final OA Apr 12, 2023
17819182 ENGINEERED ANTI-HER2 BISPECIFIC PROTEINS ALLEN, MICHAEL D 1671 Non-Final OA Aug 11, 2022
17797644 METHODS FOR THE TREATMENT OF HUNTER SYNDROME CHANDRA, GYAN 1674 Non-Final OA Aug 04, 2022
17296506 METHODS FOR TREATING DYSREGULATED LIPID METABOLISM AEDER, SEAN E 1642 Non-Final OA May 24, 2021
17178595 ANTI-HER2 POLYPEPTIDES AND METHODS OF USE THEREOF SHUPE, ELIZABETH A 1643 Final Rejection Feb 18, 2021

Managing Denali Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month